Skip to content

Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients – a randomized rater-blinded trial

Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients – a randomized rater-blinded trial - P4D-2A

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00032503
Enrollment
256
Registered
2023-08-17
Start date
2024-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32.2 F32.3 F33.2 F33.3

Interventions

Group 1: 128 patients and their treating physicians receive information about the BDNF IV CpG-87 status of the patient. Group 2: 128 patients and treating physicians do not receive information about t

Sponsors

Medizinische Hochschule Hannover
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: - Severity of symptoms: Severe (HDRS-24 = 25) - Change of therapy / alteration of medication therapy - First depressive episode before the age of 50 - Signed informed consent - Capacity to provide consent

Exclusion criteria

Exclusion criteria: - Acute suicidality - Involuntary placement according to state law (e.g., §16/17 Nds. PsychKG) - Persistent depressive disorder (PDD) - Following diagnoses in medical history: Dementia, schizophrenia, schizoaffective disorder, bipolar disorder, substance dependence with current necessary detoxification - Simultaneous participation in other clinical studies not conducted within the scope of the P4D project

Design outcomes

Primary

MeasureTime frame
Two (co-)primary endpoints: 1.: Co-primary Efficacy Endpoint: Remission rate of depressive symptoms 6 weeks post-randomization determined by an HDRS-24 total score = 10. 2.: Co-primary Tolerance Endpoint: Rate of adverse events (AE) within 6 weeks post-randomization.

Secondary

MeasureTime frame
Remission 10 weeks after randomization (HDRS-24 total scores = 10), adverse events 10 weeks after randomization, prescription rate of antidepressants, frequency of changes in therapy regimens during study participation; frequency of specific psychotherapy application; frequency of additional treatment options' utilization; frequency and reasons for study discontinuations; attitudes (acceptance, fears, and prejudices) towards biomarker-guided investigations and technical procedures in the population (representative population survey). Patient-physician relationship.

Countries

Germany

Contacts

Public ContactHelge Frieling

Medizinische Hochschule Hannover

frieling.helge@mh-hannover.de0049 511 532 2724

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026